KARCI, E. Et Al. 2024. Neoadjuvant Pembrolizumab Plus Chemotherapy in Early-Stage Triple-Negative Breast Cancer: A Nationwide Retrospective Turkish Oncology Group Study. CANCERS , no.19 .

KARCI, E., BİLİCİ, A., Bayram, B., Celayir, M., Ozyurt, N., OYAN ULUÇ, B., ... Eken, A.(2024). Neoadjuvant Pembrolizumab Plus Chemotherapy in Early-Stage Triple-Negative Breast Cancer: A Nationwide Retrospective Turkish Oncology Group Study. CANCERS , no.19.

KARCI, Ebru Et Al. "Neoadjuvant Pembrolizumab Plus Chemotherapy in Early-Stage Triple-Negative Breast Cancer: A Nationwide Retrospective Turkish Oncology Group Study," CANCERS , no.19, 2024

KARCI, Ebru Et Al. "Neoadjuvant Pembrolizumab Plus Chemotherapy in Early-Stage Triple-Negative Breast Cancer: A Nationwide Retrospective Turkish Oncology Group Study." CANCERS , no.19, 2024

KARCI, E. Et Al. (2024) . "Neoadjuvant Pembrolizumab Plus Chemotherapy in Early-Stage Triple-Negative Breast Cancer: A Nationwide Retrospective Turkish Oncology Group Study." CANCERS , no.19.

@article{article, author={Ebru KARCI Et Al. }, title={Neoadjuvant Pembrolizumab Plus Chemotherapy in Early-Stage Triple-Negative Breast Cancer: A Nationwide Retrospective Turkish Oncology Group Study}, journal={CANCERS}, year=2024}